Stock views on Anant Raj Industries, Vivimed Labs, KEI Industries

FinQuest Securities on KEI Industries - Target Rs 49

FinQuest Securities has recommended a buy rating on KEI Industries with a target price of Rs 49 in its research report.

"With capacity expansion in place, growth in infrastructure investments, we expect KEI to return on a strong growth path. We expect the EPS of the company to be at INR 6.1 in FY11E from INR 0.2 in FY09. The company is currently trading at 4.9x and 4.6x its FY11E PE and EV/EBITDA respectively. We rate the stock as 'BUY' with a target price of INR 49.0," says FinQuest Securities' report.


Sunidhi Securities & Finance on Vivimed Labs - Target Rs 120

Sunidhi Securities & Finance has recommended a buy rating on Vivimed Labs with a target price of Rs 120 in its research report.

"Vivimed’s vide range of specialty chemicals, leading global clientele base in the FMCG space, sizable demand of its products, outsourcing potential and improving performance give strong visibility to revenue & profitability in the future. We recommend 'BUY' with a target price of Rs 120 in the medium term," says Sunidhi Securities & Finance's research report.


Motilal Oswal on Anant Raj Industries - Target Rs 194

Motilal Oswal has recommended a buy rating on Anant Raj Industries with a target price of Rs 194 in its research report.

"ARIL has a robust business model with multiple revenue streams and high monetization visibility. We expect revenues to increase at 50% CAGR over FY09- 12 and net profit to increase at 18.2% over FY09-12. The stock trades at 1.1x FY11E BV of Rs 127 and 27% discount to its FY11 NAV of Rs 194, which is attractive compared to industry peers that trade at 1.7x FY11E BV and 2% premium to NAV. We initiate coverage with Buy; our target price is of Rs 194," says Motilal Oswal's research report.